Central Serous Chorioretinopathy: Causes, Treatment, and Recovery
Understanding Central Serous Chorioretinopathy
CSCR develops when fluid leaks from the blood vessel layer beneath the retina and collects in a small pocket under the macula, the part of the eye responsible for sharp central vision. Understanding what happens inside the eye helps explain why symptoms appear and why treatment choices vary from person to person.
The retina rests on a layer of support cells called the retinal pigment epithelium, or RPE. Beneath the RPE lies the choroid, a tissue layer filled with blood vessels that delivers oxygen and nutrients to the retina. In CSCR, the choroidal blood vessels become overly permeable, meaning they leak more fluid than normal, while the RPE loses its ability to pump that excess fluid away.
When fluid accumulates beneath the retina, it creates a small blister-like separation right at the macula. This pushes the retina slightly out of position, which is why people with CSCR experience blurred or distorted central vision.
In patients with CSCR, the choroid is often thicker than normal. This thickening is linked to increased pressure and leakage within the choroidal blood vessels. Proteins called mineralocorticoid receptors, found in retinal cells, are thought to play a role. When these receptors become overactivated, the choroidal blood vessels can dilate and leak, setting off the fluid buildup that defines CSCR.
CSCR is generally classified into two forms. Acute CSCR involves a single episode of fluid buildup that typically resolves on its own within two to three months, and most people with this form recover good vision, though it may not return to exactly what it was before the episode.
Chronic CSCR occurs when fluid persists beyond three to four months or keeps returning over time. Chronic cases carry a higher risk of permanent damage to the retina and RPE. Retina specialists may also classify CSCR into simple and complex subtypes based on imaging findings, which helps guide treatment decisions more precisely.
Who Gets CSCR and Why
CSCR does not affect everyone equally. Certain groups of people face a higher risk, and understanding these risk factors can help with early recognition and prevention of recurrence.
CSCR most commonly affects adults between the ages of 30 and 50. Men are significantly more likely to develop the condition than women, occurring roughly six times more often in men. The median age at diagnosis tends to be slightly younger for men than for women, and large population studies have confirmed that male patients represent the majority of CSCR cases.
Corticosteroid use is one of the strongest and most well-established risk factors for CSCR. This includes corticosteroids taken by mouth, inhaled for asthma, applied to the skin, injected into joints, or used as nasal allergy sprays. Even over-the-counter products that contain corticosteroids can increase the risk.
If a patient is diagnosed with CSCR, our retina specialists will ask about all forms of corticosteroid exposure and may recommend reducing or stopping these medications when it is medically safe to do so.
Psychological stress is a well-recognized trigger for CSCR. During periods of intense stress, the body produces natural corticosteroids such as cortisol, which may contribute to fluid leakage in the choroid. People with highly competitive or high-pressure lifestyles, sometimes described as having a type A personality, appear to face a greater risk. Addressing stress may play a supportive role in reducing the chance of recurrence.
Several additional factors have been linked to an increased risk of developing CSCR.
- Pregnancy, likely due to elevated natural corticosteroid levels
- Cushing syndrome, a condition in which the body produces too much cortisol on its own
- Helicobacter pylori infection, a bacterial infection affecting the stomach
- Autoimmune conditions
- Sleep disturbances, including insomnia and obstructive sleep apnea
- Family history of CSCR, with roughly half of patients having at least one relative with signs of the disease on retinal examination
Signs and Symptoms of CSCR
CSCR typically affects one eye at a time, though both eyes can be involved. Symptoms range from obvious blurring to more subtle changes that may only be noticed when one eye is covered.
The most common symptom of CSCR is blurred central vision, often described as looking through a smudge or a light haze. Many patients also experience metamorphopsia, which means straight lines or shapes appear wavy, bent, or distorted when viewed with the affected eye. These changes occur because the fluid beneath the retina pushes it slightly out of its normal position.
Some people notice micropsia, a condition where objects look smaller than they actually are. Colors may appear washed out or slightly different compared to the unaffected eye. A dim spot or partial blind spot in the center of vision, called a relative scotoma, can also occur. These subtler symptoms may only become apparent when each eye is tested separately.
While CSCR itself is not typically a medical emergency, some symptoms can overlap with more serious conditions such as retinal detachment. Anyone who experiences a sudden dark curtain or shadow moving across their vision, sudden vision loss, or a sharp increase in floaters accompanied by flashes of light should seek immediate evaluation at a retina specialist's office or an emergency room. These symptoms may signal a different and more urgent problem that requires prompt treatment.
How CSCR Is Diagnosed
Accurate diagnosis of CSCR requires a combination of a careful eye examination and specialized imaging tests. These tools allow our retina specialists to confirm the diagnosis, locate the source of the fluid leak, and plan the most appropriate course of care.
A retina specialist will begin with a comprehensive eye examination that includes dilating the pupils with eye drops. This allows a detailed view of the retina and macula. In many cases, the specialist can see a dome-shaped area of fluid under the macula during this exam. Imaging tests are then used to confirm the diagnosis and assess the extent of the condition.
Optical coherence tomography, commonly known as OCT, is the primary imaging tool for diagnosing and monitoring CSCR. OCT uses light waves to produce detailed cross-sectional images of the retina, clearly showing the pocket of fluid beneath it and measuring how much fluid is present. This test is also used at follow-up visits to track whether the fluid is resolving or worsening over time.
Fluorescein angiography involves injecting a yellow dye into a vein in the arm. As the dye travels through the blood vessels of the eye, a specialized camera captures images of the retinal and choroidal circulation. In CSCR, this test often reveals a single leakage point from the RPE that spreads outward in a pattern sometimes described as a smokestack or inkblot. This helps pinpoint the exact location of the leak.
Indocyanine green angiography, or ICG angiography, uses a different dye that is better suited for imaging the deeper choroidal blood vessels. This test helps evaluate the extent of choroidal thickening and increased vessel permeability that are characteristic of CSCR. Some specialists also use OCT angiography, a noninvasive technique that maps blood flow in the retina and choroid without requiring a dye injection. Together, these imaging tools help classify the type and severity of CSCR and guide treatment planning.
Treatment Options for CSCR
Treatment for CSCR depends on whether the condition is acute or chronic, how long the fluid has been present, and where the leakage point is located. Our retina specialists will recommend the most appropriate approach based on each patient's imaging findings and clinical situation.
For most acute CSCR cases, the initial approach is careful observation. The majority of acute episodes resolve on their own within two to three months as the RPE regains its ability to pump fluid away from the retina. During this period, follow-up visits and OCT scans are scheduled to monitor the fluid closely. Our specialists may also recommend stopping corticosteroid medications and addressing modifiable risk factors such as stress and poor sleep.
For chronic CSCR or cases that do not resolve on their own, half-dose photodynamic therapy, or PDT, is among the most effective treatments available. A light-sensitive medication called verteporfin is injected into a vein, and a low-energy laser is then directed at the affected area of the choroid. The laser activates the medication and helps seal the leaking blood vessels. Using half the standard drug dose reduces the risk of side effects while maintaining effectiveness.
Clinical trial data has shown that a substantial majority of patients treated with half-dose PDT achieve complete resolution of subretinal fluid within three months, and outcomes continue to improve over the following year. This approach is currently considered a leading treatment for chronic CSCR.
Focal laser photocoagulation uses thermal laser energy to seal the specific RPE leakage point. This option may be considered when the leak is located away from the very center of the macula, since applying laser to the central fovea (the most sensitive part of the macula) could damage central vision. Focal laser can speed fluid resolution but is used selectively based on the location of the leakage point.
Some retina specialists have explored oral medications for chronic CSCR. Eplerenone, a mineralocorticoid receptor blocker, was studied as a potential treatment. However, a well-designed clinical trial found that eplerenone showed no significant benefit over placebo in patients with chronic CSCR lasting more than four months. Despite this, a related medication called spironolactone may be considered in certain situations, though the evidence for its effectiveness remains limited. Our specialists will discuss whether oral medications are appropriate for each patient's individual case.
Anti-VEGF injections, which target a protein called vascular endothelial growth factor, are not a standard treatment for typical CSCR. However, some patients with long-standing chronic CSCR develop choroidal neovascularization, a complication in which abnormal new blood vessels grow beneath the retina. When this complication is detected on imaging, anti-VEGF injections may be recommended to block the growth and leakage of these abnormal vessels. Our retina specialists will use imaging tests to determine whether this complication is present and whether this treatment is appropriate.
What to Expect Over Time
The outlook for CSCR varies depending on whether the condition is acute, chronic, or recurrent. Understanding what recovery and long-term monitoring look like helps patients stay engaged in their care.
Most patients with a first episode of acute CSCR can expect the fluid to resolve within two to three months. As the fluid absorbs, vision gradually improves. However, some patients find that their vision does not return completely to its previous level. Subtle differences in contrast sensitivity, color perception, or mild distortion may persist even after the fluid is fully gone. These residual changes are often related to the stress placed on the RPE and photoreceptor cells during the episode.
One of the most important aspects of CSCR is its tendency to return. Approximately half of patients who have had an episode of CSCR will experience a recurrence at some point, sometimes months or years after the first episode. Each recurrence carries the potential for additional damage to the macula. For this reason, our specialists recommend ongoing monitoring even after the fluid has fully resolved, along with continued attention to avoiding known triggers such as corticosteroid use and unmanaged stress.
Chronic CSCR requires closer monitoring and often active treatment. Prolonged fluid beneath the retina can cause permanent thinning and damage to both the RPE and the photoreceptor cells above it, leading to lasting vision loss over time. Early treatment of chronic cases is important to minimize permanent structural changes to the retina. Real-world data from patients treated with half-dose PDT has shown meaningful improvements in visual sharpness and measurable reductions in retinal thickness, underscoring the value of timely intervention.
Living With CSCR
Patients with CSCR can take an active role in protecting their vision between office visits. A few consistent habits can meaningfully reduce the risk of recurrence and help catch problems early.
The most impactful step patients can take is avoiding corticosteroid medications whenever possible. This means informing all healthcare providers, including primary care physicians and specialists, about a CSCR diagnosis so that non-steroidal alternatives can be considered when appropriate. Stress reduction strategies such as regular exercise, consistent sleep, mindfulness practices, and professional counseling may also support overall eye health and reduce the likelihood of recurrence.
Our retina specialists often recommend that patients with a history of CSCR monitor their vision regularly at home using an Amsler grid, a card with a grid pattern of straight lines. By looking at the grid with each eye separately, a patient can detect new distortion, blurring, or missing areas that may signal a return of fluid beneath the retina. Any new or worsening visual symptoms should prompt a prompt visit with a retina specialist for evaluation.
Even after a single episode of CSCR resolves completely, periodic follow-up with a retina specialist is recommended. These visits typically include OCT imaging to check for subtle fluid that may not yet cause noticeable symptoms. Patients with chronic or recurrent CSCR may need more frequent appointments. Long-term follow-up also helps detect complications such as choroidal neovascularization at an early and more treatable stage.
Frequently Asked Questions
Below are answers to questions we commonly hear from patients managing CSCR. These responses are intended to add context and practical guidance beyond what is covered above.
For most patients with a single acute episode, permanent vision loss is uncommon, though some subtle changes in contrast or color perception may linger even after full fluid resolution. The greater risk comes with chronic or frequently recurring CSCR, where prolonged fluid accumulation gradually damages the RPE and photoreceptor cells. This is why early evaluation, consistent follow-up, and timely treatment for chronic cases are so important. Waiting to seek care can increase the risk of changes that do not fully reverse.
Even nasal allergy sprays that contain corticosteroids can potentially trigger or worsen CSCR, because some of the medication is absorbed into the bloodstream. Patients with a CSCR history should let all of their doctors know about the condition before starting any corticosteroid-containing product, including over-the-counter options. In many cases, non-steroidal alternatives for allergy management are available. Patients should never discontinue a prescribed medication without consulting the prescribing provider first.
Both CSCR and age-related macular degeneration, or AMD, affect the macula, but they are distinct diseases with different causes, age profiles, and treatment approaches. CSCR typically affects adults in their 30s through 50s and involves fluid leaking from the choroid through the RPE. AMD predominantly affects older adults and involves a different disease process, including the buildup of deposits called drusen in dry AMD and the growth of abnormal blood vessels in wet AMD. A retina specialist can reliably distinguish between these conditions using imaging, which is essential since their management differs significantly.
Stress management on its own is unlikely to clear an active fluid accumulation, particularly in chronic cases. However, because psychological stress causes the body to produce cortisol, which may worsen choroidal leakage, reducing stress is still a worthwhile part of overall management. Consistent physical activity, healthy sleep habits, and professional support for anxiety or high-stress circumstances may help lower the risk of future episodes. Think of stress reduction as a complementary strategy alongside medical care, not a replacement for it.
Follow-up frequency is tailored to each patient's situation. During an active episode, visits are typically scheduled every four to six weeks to monitor fluid levels with OCT imaging. Once the fluid resolves, appointments may shift to every three to six months during the first year and then annually if the condition remains stable. Patients receiving treatment such as photodynamic therapy, or those with chronic or recurrent disease, will generally need more frequent monitoring. Our retina specialists will build a schedule that fits your specific clinical picture and adjust it as your condition evolves.
CSCR most commonly affects one eye at a time, which is why patients often notice a clear difference between how each eye sees. However, involvement of both eyes, whether simultaneously or at different times, does occur in some cases. When both eyes appear affected, specialists may look more closely for underlying causes such as systemic corticosteroid use or Cushing syndrome. Imaging both eyes at each visit allows our team to detect early changes in the second eye even before symptoms develop.
Expert Retina Care at Rhode Island Eye Institute
Rhode Island Eye Institute is home to fellowship-trained retina specialists who have extensive experience diagnosing and treating CSCR at every stage, from a first acute episode to complex chronic cases. Our team combines advanced diagnostic imaging with individualized treatment plans to give each patient the clearest path forward. We welcome you to schedule a comprehensive evaluation and experience the level of subspecialty care that has earned the trust of thousands of patients across our region.